McKesson Co. (NYSE:MCK) Shares Acquired by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH increased its stake in shares of McKesson Co. (NYSE:MCK - Free Report) by 623.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 31,470 shares of the company's stock after purchasing an additional 27,119 shares during the quarter. McKesson accounts for approximately 0.7% of Siemens Fonds Invest GmbH's holdings, making the stock its 24th biggest position. Siemens Fonds Invest GmbH's holdings in McKesson were worth $17,935,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Frank Rimerman Advisors LLC lifted its holdings in shares of McKesson by 2.2% in the 4th quarter. Frank Rimerman Advisors LLC now owns 807 shares of the company's stock valued at $460,000 after buying an additional 17 shares during the period. Hemington Wealth Management grew its holdings in McKesson by 18.6% during the fourth quarter. Hemington Wealth Management now owns 115 shares of the company's stock worth $65,000 after acquiring an additional 18 shares during the period. First Western Trust Bank raised its position in McKesson by 2.0% in the fourth quarter. First Western Trust Bank now owns 931 shares of the company's stock worth $531,000 after acquiring an additional 18 shares in the last quarter. Calamos Wealth Management LLC lifted its holdings in McKesson by 0.4% in the fourth quarter. Calamos Wealth Management LLC now owns 4,677 shares of the company's stock valued at $2,665,000 after acquiring an additional 20 shares during the period. Finally, Quent Capital LLC boosted its position in shares of McKesson by 1.7% during the 4th quarter. Quent Capital LLC now owns 1,178 shares of the company's stock worth $671,000 after purchasing an additional 20 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CAO Napoleon B. Rutledge, Jr. sold 543 shares of the business's stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $726.51, for a total value of $394,494.93. Following the completion of the sale, the chief accounting officer now directly owns 1,972 shares in the company, valued at approximately $1,432,677.72. The trade was a 21.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Leann B. Smith sold 341 shares of the company's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $717.91, for a total transaction of $244,807.31. Following the transaction, the executive vice president now directly owns 2,800 shares of the company's stock, valued at $2,010,148. This trade represents a 10.86% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,856 shares of company stock worth $7,793,675. 0.11% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MCK shares. Cfra Research downgraded shares of McKesson from a "moderate buy" rating to a "hold" rating in a report on Friday, April 4th. Morgan Stanley increased their target price on shares of McKesson from $642.00 to $745.00 and gave the company an "overweight" rating in a report on Wednesday, April 2nd. Wall Street Zen downgraded shares of McKesson from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 21st. UBS Group upped their price target on McKesson from $708.00 to $805.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Finally, Mizuho raised their price objective on McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a research note on Thursday, April 3rd. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, McKesson has a consensus rating of "Moderate Buy" and an average target price of $686.69.

McKesson Trading Up 1.0%

Shares of NYSE:MCK traded up $6.99 on Friday, hitting $719.85. The company had a trading volume of 1,322,220 shares, compared to its average volume of 916,535. The company has a market cap of $90.06 billion, a PE ratio of 32.96, a PEG ratio of 1.29 and a beta of 0.53. McKesson Co. has a 52-week low of $464.42 and a 52-week high of $731.00. The business has a 50 day moving average of $694.04 and a 200 day moving average of $636.97.

McKesson (NYSE:MCK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $10.12 earnings per share for the quarter, beating the consensus estimate of $9.83 by $0.29. McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. The firm had revenue of $90.82 billion during the quarter, compared to the consensus estimate of $94 billion. During the same quarter in the previous year, the company posted $6.18 EPS. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. As a group, equities analysts predict that McKesson Co. will post 32.77 EPS for the current year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Monday, June 2nd will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Monday, June 2nd. This represents a $2.84 dividend on an annualized basis and a yield of 0.39%. McKesson's dividend payout ratio (DPR) is currently 10.99%.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.